Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Sebe

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
European Review for Medical and Pharmacological Sciences|November 1, 2013
Acute-phase reactants and cytokines in ischemic stroke: do they have any relationship with short-term mortality?M Sahan, A Sebe, A Acikalin, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 25, 2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TBC D Tweed, G H Wills, A M Crook, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
European Review for Medical and Pharmacological Sciences|November 1, 2013
Acute-phase reactants and cytokines in ischemic stroke: do they have any relationship with short-term mortality?M Sahan, A Sebe, A Acikalin, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 25, 2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TBC D Tweed, G H Wills, A M Crook, et al.
Pageof 2